Top Markets
#1 DogBull DogBull +105.03%
#2 ADO Protocol ADO Protocol +63.41%
#3 Siacoin Siacoin +46.50%
#4 MarsCoin MarsCoin +37.49%
#5 Useless Coin Useless Coin +36.09%
#6 Ontology Gas Ontology Gas +27.76%
#7 UnifAI Network UnifAI Network +27.18%
#8 Glidr Glidr +19.86%
#9 Falcon Finance Falcon Finance +17.20%
#10 Apertum Apertum +14.82%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Duopharma Biotech Berhad Duopharma Biotech Berhad

Duopharma Biotech Berhad

7148
Rank in Stocks #16074
Duopharma Biotech Berhad, an investment holding firm, is actively engaged in... Duopharma Biotech Berhad, an investment holding firm, is actively engaged in the pharmaceutical sector. Its operations encompass the research, development, manufacturing, distribution, and import of medicinal products, serving markets in Malaysia and internationally. The company's extensive product range includes consumer health items like vitamins, nutritional supplements, pain relievers, eye care solutions, antacids, and skincare products. It also provides generic medications across various therapeutic classes, such as cardiovascular, dermatological, hormonal, respiratory, neurological, musculoskeletal, and anti-infective agents. Furthermore, Duopharma offers specialized pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables, addressing ailments like diabetes, cancer, cardiovascular diseases, and renal disorders. Notable products include vascor, insugen, kytron, and unihepa. Its well-known brands feature Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol. Beyond its core pharmaceutical activities, the company is also involved in property management and the trading of chemical products. Founded in 1978 and headquartered in Kuala Lumpur, Malaysia, the company adopted its current name, Duopharma Biotech Berhad, in February 2019, having previously been known as CCM Duopharma Biotech Berhad.
Share Price
$0.32757535
Market Cap
$315.11M
Change (1 day)
0.00%
Change (1 year)
1.02%
Country
MY
Trade Duopharma Biotech Berhad (7148)

Category

Healthcare
Revenue for Duopharma Biotech Berhad (7148)
Revenue in Sep 2026 TTM: 0
According to Duopharma Biotech Berhad latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Duopharma Biotech Berhad from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH